WELIREG

Generic Name/API: belzutifan

Manufacturer: Merck Sharp & Dohme

Dosage Forms & Strength & Pack Size:
Tablets: 40 mg. 90’s

Storage:
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).

  • INDICATION
  • IMPORTANT SAFETY INFORMATION

INDICATION

What is WELIREG?
WELIREG is a prescription medicine used to treat adults with von Hippel-Lindau (VHL) disease who need treatment for a type of kidney cancer called renal cell carcinoma (RCC), tumors in the brain and spinal cord called central nervous system (CNS) hemangioblastomas, or a type of pancreatic cancer called pancreatic neuroendocrine tumors (pNET), that do not need surgery right away.

WELIREG is a prescription medicine used to treat adults with kidney cancer that has spread (advanced RCC) following treatment with a PD-1 or PD-L1 and VEGF cancer medicines.

It is not known if WELIREG is safe and effective in children.

PD⁠-⁠1 = programmed death receptor⁠-⁠1;
PD⁠-⁠L1 = programmed death⁠-⁠ligand 1;
VEGF = vascular endothelial growth factor.

IMPORTANT SAFETY INFORMATION

WELIREG may cause serious side effects. WELIREG may cause harm to your unborn baby.

A pregnancy test will be done before you start treatment.
Birth control methods that contain hormones may not work as well during treatment.
Females and males with female partners who can become pregnant should use an effective form of non-hormonal birth control (contraception) during treatment and for 1 week after your last dose.
WELIREG may cause serious side effects, including:

Low red blood cell counts (anemia). Low red blood cell counts are common with WELIREG and can be severe. You may need a blood transfusion if your red blood cell counts drop too low. Your health care provider will do blood tests to check your red blood cell counts before you start and during treatment with WELIREG. Tell your health care provider if you get any symptoms of low red blood cell counts, including tiredness, feeling cold, shortness of breath, chest pain, or fast heartbeat.

Low oxygen levels in your body. WELIREG can cause low oxygen levels in your body that can be severe and may require you to stop treatment with WELIREG, receive oxygen therapy, or be hospitalized. Your health care provider will monitor your oxygen levels before you start and during treatment with WELIREG. Tell your health care provider or get medical help right away if you get symptoms of low oxygen in your body, including shortness of breath or increased heart rate.

Harm to your unborn baby. Treatment with WELIREG during pregnancy can cause harm to your unborn baby.

Females who are able to become pregnant:

Your health care provider will do a pregnancy test before you start treatment with WELIREG.
You should use an effective form of non-hormonal birth control (contraception) during treatment with WELIREG and for 1 week after your last dose.
Birth control methods that contain hormones (such as birth control pills, injections, or transdermal system patches) may not work as well during treatment with WELIREG.
Talk to your health care provider about birth control methods that may be right for you during treatment with WELIREG.
Tell your health care provider right away if you become pregnant or think you may be pregnant during treatment with WELIREG.
Males with female partners who are able to become pregnant:

You should use effective birth control (contraception) during treatment with WELIREG and for 1 week after your last dose.
Tell your health care provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking WELIREG.
Before taking WELIREG, tell your health care provider about all of your medical conditions, including if you:

have low red blood cell counts (anemia)
are pregnant or plan to become pregnant
are breastfeeding or plan to breastfeed. It is not known if WELIREG passes into your breast milk. Do not breastfeed during treatment with WELIREG and for 1 week after your last dose.
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. WELIREG and certain other medicines can affect each other and cause serious side effects.

The most common side effects of WELIREG in adults with VHL disease include:

tiredness
increased creatinine (kidney function test)
headache
dizziness
increased blood sugar (glucose) levels
nausea
The most common side effects of WELIREG in adults with advanced RCC include:

tiredness
decreased white blood cells
increased creatinine (kidney function test)
muscle and joint pain
increased liver function tests
decreased blood salts (sodium) levels
increased blood potassium levels
WELIREG may cause fertility problems in males and females, which may affect your ability to have children. Talk to your health care provider if this is a concern for you.

Scroll to Top